Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w/Peritoneal Carcinomatosis (STOPGAP-B)

Part of paid clinical trials in Orange, California.

Sponsor: University of California, Irvine
Study ID: NCT07795749
Phase: PHASE2
Status: Recruiting

Apply to this trial

Conditions

Appendiceal Adenocarcinoma
Colorectal Adenocarcinoma
Esophageal Carcinoma
Gastric Cancer (Diagnosis)
Hepatobiliary Carcinoma in Situ
Small Bowel Adenocarcinoma

Eligibility Criteria

Sex: ALL
Age: 18 Years - N/A
Healthy Volunteers: Not accepted

Interventions

Paclitaxel Q2W — DRUG
Given IP-IV, every 2 weeks
Paclitaxcel Q3W — DRUG
Given IP-IV, every 3 weeks

Study Details

This is a phase II open-label, basket clinical trial to assess the feasibility of systemic and Intraperitoneal chemotherapy in subjects with Gastrointestinal Malignancies with Peritoneal Carcinomatosis. These are subjects who have a proven primary carcinoma of the digestive tract..

Key Dates

First listed: Aug 31, 2026
Start date: Aug 4, 2026
Status verified: Aug 2026
Primary completion: Aug 31, 2029
Completion: Aug 31, 2029

Study Design

Enrollment: 55 participants (estimated)
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Arms

Experimental: CohtAQ2W: Chort A Gastric/Esophageal Carcinoma (Paclitaxel Q2W)
Experimental: CohtAQ3W: Cohort A Gastric/Esophageal Carcinoma (Paclitaxel Q3W)
Experimental: CohtBQ2W: Cohort B Colorectal/Appendiceal Adenocarcinoma (Paclitaxel Q2W)
Experimental: CohtBQ3W: Cohort B Colorectal/Appendiceal Adenocarcinoma (Paclitaxel Q3W)
Experimental: CohtCQ2W: Cohort C Other Malignancies of the Digestive Tract (Paclitaxel Q2W)
Experimental: CohtCQ3W: Cohort C Other Malignancies of the Digestive Tract (Paclitaxel Q3W)